The concern of generic rivalry has long loomed around copyright’s famous drug, Viagra, sparking questions about the future of connected drug holdings. While early years saw substantial gains, the exclusivity expiration has created the path for cheaper substitutes, potentially lowering earnings and creating a significant risk for shareholders purs